Result of AGM

RNS Number : 7108F

Hikma Pharmaceuticals Plc

19 May 2017

 

Hikma Pharmaceuticals PLC

Voting Results of 2017 Annual General Meeting

LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 19 were passed as ordinary resolutions and Resolutions 20 to 23 were passed as special resolutions.

As previously announced, Mr. Michael Ashton retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility. 

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2017) is set out below. The number of Ordinary Shares in issue on 19 May 2017 was 240,380,475.

Resolution	Votes For	%	Votes Against	%	Withheld	Total Cast
1. To receive the 2016 report and accounts	197,423,759	99.84%	319,920	0.16%	6,643	197,750,322
2. To approve a final dividend of 22 cents per share	197,743,879	100.00%	0	0.00%	6,443	197,750,322
3. To re-appoint PricewaterhouseCoopers LLP as auditors	197,741,251	100.00%	905	0.00%	8,166	197,750,322
4.To authorise the Audit Committee to determine the auditors' remuneration	197,688,953	99.97%	53,203	0.03%	8,166	197,750,322
5. To elect Nina Henderson as a director	197,534,627	99.89%	208,786	0.11%	6,854	197,750,267
6. To re-elect Said Darwazah as a director	193,519,353	98.05%	3,848,526	1.95%	382,442	197,750,321
7. To re-elect Mazen Darwazah as a director	195,813,592	99.21%	1,551,895	0.79%	384,835	197,750,322
8. To re-elect Robert Pickering as a director	197,076,319	99.66%	667,559	0.34%	6,443	197,750,321
9.To re-elect Ali Al-Husry as a director	196,769,085	99.57%	857,947	0.43%	123,290	197,750,322
10. To re-elect Dr. Ronald Goode as a director	195,703,815	98.97%	2,039,923	1.03%	6,584	197,750,322
11. To re-elect Patrick Butler as a director	197,506,890	99.88%	236,848	0.12%	6,584	197,750,322
12. To re-elect Dr. Jochen Gann as a director	196,795,912	99.58%	830,979	0.42%	123,431	197,750,322
13. To re-elect John Castellani as a director	197,586,602	99.92%	157,277	0.08%	6,443	197,750,322
14. To re-elect Dr. Pamela Kirby as a director	195,665,777	98.96%	2,053,602	1.04%	6,468	197,725,847
15. To approve the directors' remuneration policy	169,053,856	86.39%	26,622,257	13.61%	2,074,207	197,750,320
16. To approve the remuneration report for the year ended 31 December 2016	193,651,599	97.93%	4,091,754	2.07%	6,968	197,750,321
17. To approve the extension of the effective period of the Executive Incentive Plan	170,276,525	86.12%	27,450,966	13.88%	22,830	197,750,321
18. To approve the increase of the aggregate directors' fee limit	197,640,307	99.98%	45,091	0.02%	64,924	197,750,322
19. Authority to allot shares	170,146,304	86.21%	27,221,034	13.79%	382,984	197,750,322
20. To dis-apply pre-emption rights for general purposes	196,872,145	99.56%	869,023	0.44%	9,154	197,750,322
21. To dis-apply pre-emption rights for an acquisition or other capital investment	173,591,716	87.79%	24,149,939	12.21%	8,666	197,750,321
22. To authorise the Company to purchase its own shares	197,014,413	99.66%	676,265	0.34%	59,643	197,750,321
23. To authorise the Company to hold general meetings on no less than 14 clear days' notice	187,053,655	94.82%	10,213,802	5.18%	482,864	197,750,321

Declaration of final dividend

The dividend of 22 cents per share will be paid on 25 May 2017 to shareholders on the register on 7 April 2017.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.2898 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]
Susan Ringdal VP for Investor Relations and Strategy	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe.  In 2016, Hikma achieved revenue of $1,950 million and profit attributable to shareholders of $155 million. In the United States, Hikma operates through its wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with operations based in New Jersey, Ohio and Tennessee. For more information visit www.hikma.com.

 

END

 

 

RAGSFEFDUFWSELI